

March 1, 2021



## Trevena, Inc. to Participate in March Virtual Investor Conferences

CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- **Trevena, Inc. (Nasdaq: TRVN)**, a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in two upcoming virtual investor conferences in March. Additional details are below:

### H.C. Wainwright Global Life Sciences Conference

**Date:** Tuesday, March 9<sup>th</sup>

**Format:** One-on-one investor meetings

Carrie Bourdow, President & Chief Executive Officer

**Attendees:** Barry Shin, SVP & Chief Financial Officer

Mark A. Demitrack, M.D., SVP & Chief Medical Officer

### Oppenheimer 31<sup>st</sup> Annual Healthcare Conference

**Date:** Tuesday, March 16<sup>th</sup>

**Format:** Corporate Presentation & One-on-one investor meetings

**Time:** 3:50 p.m. ET

Carrie Bourdow, President & Chief Executive Officer

Barry Shin, SVP & Chief Financial Officer

**Attendees:** Mark A. Demitrack, M.D., SVP & Chief Medical Officer

**Webcast:** <https://wsw.com/webcast/oppenheimer9/trvn/2777522>

A link to the webcast for the Oppenheimer presentation will be available on the Events page of the Investors section of the Company's website at: <https://www.trevena.com/investors/events-presentations/ir-calendar>. A replay of the presentation will be archived on the website and available for approximately 90 days following the event.

### About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and

differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

For more information, please visit [www.Trevena.com](http://www.Trevena.com).

### **Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "objective," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," "ongoing," or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company's clinical trials or any future trials of any of the Company's investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company's assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company's intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

### **Investor Contact:**

Daniel Ferry  
LifeSci Advisors  
Phone: 617-430-7576  
Email: [IR@trevena.com](mailto:IR@trevena.com)

### **Company Contact:**

Bob Yoder, SVP and Chief Commercial Officer  
Trevena, Inc.  
Phone: 610-354-8840



Source: Trevena Inc.